COMPANY INFO
NeuroFlow, founded in 2017 by Christopher Molaro and Adam Pardes, is a privately held company headquartered in Philadelphia, PA. With about 153 employees, NeuroFlow operates in the Outcome Management (Healthcare) industry, providing a digital platform that integrates mental health programs with measurement-based care and consumer engagement to optimize behavioral health outcomes and support healthcare organizations in delivering better care.
NeuroFlow, Inc. is a privately held company established in 2017 by Christopher Molaro and Adam Pardes. Headquartered in Philadelphia, PA, this 153-employee company operates within the mental health care sector, specifically focusing on outcome management for healthcare organizations. NeuroFlow provides a digital platform that integrates mental health programs, measurement-based care, and consumer engagement, empowering healthcare systems to optimize behavioral health outcomes and deliver higher-quality care.
NeuroFlow, Inc. has pursued a robust funding strategy since its founding, securing a total of $52.5M across four main funding rounds. These rounds have equipped the company with the capital needed to develop and scale its innovative mental health solutions, expand operations, and invest in research and technology. Beginning with Series A to fuel product development, NeuroFlow evolved to attract prominent venture capital support in subsequent funding rounds, establishing strong partnerships with leading healthcare investors. The company's funding history reflects a focus on scaling its impact in behavioral health through partnerships, R&D investment, and an expanding referral network.
This latest Series C round, led by Concord Health Partners, provided NeuroFlow with growth capital to meet soaring demand for its behavioral health solutions and further expand its reach within the healthcare industry.
In a significant Series C growth investment, SEMCAP Health led a $25 million round to deepen NeuroFlow’s payor and provider relationships, expand its referral network, increase R&D, and support the company’s rapid expansion in digital behavioral health.
Led by Magellan Health, the $20 million Series B round enabled NeuroFlow to scale its operations, advance data analytics, enhance AI capabilities, and support health record integrations essential for delivering comprehensive mental health support.
The Series A round raised $7.5 million, led by Builders VC and Dreamit, to accelerate product development, establish market entry, and solidify NeuroFlow’s role at the intersection of mental health and technology.
Concord Health Partners is a healthcare-focused venture capital firm that led NeuroFlow’s most recent Series C round. Their investment demonstrates confidence in NeuroFlow’s business model and supports further expansion in the behavioral health care space.
SEMCAP Health led the $25 million Series C round, playing a pivotal role in scaling NeuroFlow’s innovation, supporting R&D, and helping establish deeper relationships within the payer and provider ecosystem.
A leader in behavioral health, Magellan Health led the $20 million Series B round. Their backing helped NeuroFlow accelerate integration with payor and provider systems and enhance data-driven healthcare delivery.
Builders VC co-led the Series A round, helping NeuroFlow advance its technology platform and establish a strong foundation for future growth.
Dreamit, a venture fund investing in healthtech and security companies, also co-led NeuroFlow’s Series A, providing early-stage support and strategic guidance.
First Trust Capital Partners has played an ongoing role as a key investor, offering additional capital and strategic insight to help fuel NeuroFlow’s mission of improving mental health outcomes.
MemorialCare Innovation Fund provides capital to high-potential health tech companies, reinforcing NeuroFlow’s capabilities in behavioral health program delivery.
Mission Daybreak is known for investing in solutions addressing mental health challenges, offering strategic support and funding to enhance NeuroFlow’s impact in the sector.
Aflac Ventures invests in promising health solutions and has contributed to NeuroFlow’s funding to support its growth and innovation initiatives.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching NeuroFlow, Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.